Primary hepatocellular carcinoma (HCC) is the third most frequent cause of cancer death in the world, and the associated morbidity and mortality have continued to rise each year [1]. There is a high prevalence of HCC in Asia, particularly in China [2]. The time-to-diagnosis plays a decisive role in disease progression, effectiveness of early
Genetic Corrected AFP Level and Liver Cancer Risk

K. Wang et al.

Genetic Corrected AFP Level and Liver Cancer Risk

Genetic Corrected AFP Level and Liver Cancer Risk

Genetic Corrected AFP Level and Liver Cancer Risk

Genetic Corrected AFP Level and Liver Cancer Risk

Genetic Corrected AFP Level and Liver Cancer Risk

Genetic Corrected AFP Level and Liver Cancer Risk

Genetic Corrected AFP Level and Liver Cancer Risk

Genetic Corrected AFP Level and Liver Cancer Risk

Genetic Corrected AFP Level and Liver Cancer Risk

Genetic Corrected AFP Level and Liver Cancer Risk
levels of AFP were measured with an Architect Ci8200 automatic analyzer (Abbott Laboratories, Abbott Park, IL) using Abbott Diagnostics reagents according to the manufacturer’s instructions, assays at baseline were all performed in the same laboratory. All samples were randomized for testing and blinded to the experimenters prior to interpretation. Values lower than the detection limit of the assay were given a “low” value of 0.005 ng/mL.

Follow-up and the diagnosis of primary hepatocellular carcinoma

The information about cancer incidence and deaths were confirmed with the unique medical insurance number for each participant from Dongfeng Medical Insurance Center’s health-care service system. The records of physical examination and questionnaire interview were also used to determine disease status and deaths. Electronic medical records in the Dongfeng Central Hospital were provided to us along with outpatient records and contact with inpatients to our database for further study. Major diseases including cancer, stroke, and diabetes were verified through reviews of medical records of the Dongfeng Central Hospital, which allowed us to obtain information on diseases and documentation of deaths in the follow-up. The definition of endpoint in this study is the incident of primary hepatocellular carcinoma. The latest follow-up of cancer in the DFTJ cohort was completed on December 31, 2016.

The diagnosis of primary hepatocellular carcinoma in this study was based on worldwide standards. The inclusion and exclusion criteria of new cases in this study were as follows: first, the diagnosis of primary hepatocellular carcinoma diagnosis was consistent with histological diagnostic criteria of the WHO [21, 22]; second, the patients who were diagnosed with metastatic hepatocellular carcinoma were excluded in this study.

Statistical analysis

The baseline characteristics of participants in this study were presented as means ± standard deviation (mean ± SD) or medians (interquartile range) for numerical variables. Student’s t-test was used to evaluate the significance differences between continuous variables. Mann–Whitney U test was used to assess for quantitative variables, where appropriate. Categorical variables were described as counts, and the Pearson chi-squared test was performed for comparison. Unconditional logistic regression model was conducted to evaluate the risk of HCC in multivariate analyses. The odds ratios (ORs) and 95% confidence intervals (95% CIs) were presented.

The genetic corrected AFP levels were estimated by combining the measured AFP levels with genetic relative effect. For each SNP associated with the serum AFP level which was found in our genome-wide association study performed before, a classical linear regression was used with log-transformed value for the standardized value, which then back-transformed to evaluate each effect of genotype, in order to test the standardized value of each SNP. The combined genetic effect was calculated based on the genotypic effect for each SNP with a multiplicative model and then combining them [18].

In addition, the area under the receiver operating characteristic (ROC) curve (AUC) with 95% confidence interval (95% CI) was used to evaluate the discriminative ability of original and genetic corrected AFP level for HCC risk. The difference of AUC between original serum AFP level and the genetic corrected AFP level were compared by a nonparametric method [23]. All two-sided P values <0.05 were considered to be statistically significant. All statistical analyses were performed using the SAS version 9.4 statistical software package and Empower Stats (http://www.empowerstats.com).

Results

Study subjects after follow-up

A total of 9819 baseline HCC-free participants were included in this study. The characteristics of all the participants enrolled in baseline including demographic, and biochemical indicators are shown in Table 1. As shown, 46.9% were males, the mean age and BMI of all study participants at baseline was 62.09 ± 7.78 years and 24.33 ± 3.32 kg/m², respectively. Among all the subjects included in the analyses, 30.3% were with a history of smoking and 27.2% were with a history of drinking.

In the period between the baseline and the follow-up, fifty-seven people were newly diagnosed with HCC (70.2% males and 29.8% females, P < 0.001). The cumulative incidence rate of HCC during the follow-up period was 5.81 cases per 1000 people. Twenty-three subjects with HCC had a history of drinking while thirty-four participants were non-drinkers. There was a significant difference in drinking history between the subjects diagnosed with HCC and those without HCC (P = 0.026). A history of smoking was also significantly higher in HCC patients (P = 0.026). However, there was no difference between the subjects with or without HCC with respect to physical activity history (P = 0.510).

Effect of SNPs on serum AFP levels

The estimates on the relative genotype effect for SNPs associated with serum AFP level are shown in Table 2. Consequently, there was a significant difference between
genetic corrected AFP levels and AFP levels alone (P < 0.001). After adjustment, the total AFP levels were estimated to be 8.7% lower than the AFP levels without adjustment (7.17 ng/mL for genetic corrected AFP levels vs. 7.85 ng/mL for the original AFP levels). Moreover, it is obvious that compared to the subjects free of HCC, the serum levels of AFP with genetic correction were higher in individuals with diagnosed HCC for the first time (3.82 ± 3.89 ng/mL vs. 2.64 ± 2.08 ng/mL, P < 0.001). The same conclusion was also presented in terms of the original serum levels of AFP.

### The risk of HCC based on serum AFP levels and genetic corrected AFP levels

The associations between the serum AFP levels and the risk of HCC are presented in Table 3. The risk of HCC elevated with the increase of serum AFP levels as well as genetic corrected AFP levels. What was more, a high OR for HCC was found in baseline AFP levels adjusting for genetic effects in three different models. The risk of HCC increased after adjusting AFP levels with genetic effects, compared to the risk predicted based on original serum AFP levels. With correction of the genetic effects, per 10 ng/mL increase of corrected AFP levels could significantly increase 434% HCC risk compared to that per 10 ng/mL increase of AFP levels only increase 404% HCC risk (OR = 5.34, 95% CI = 2.57–11.13; P < 0.001 vs. OR = 5.04, 95% CI = 2.46–10.30; P < 0.001), in the fully adjusted logistic regression model.

Table 4 represented the associations between serum AFP levels corrected with genetic effects and risk of HCC by subgroups. As shown, the risk of HCC based on serum AFP levels after adjustment of genetic effects was higher in people with a history of smoking compared to those without a smoking history (OR = 2.15, 95% CI = 1.42–3.26; P < 0.001 vs. OR = 1.19, 95% CI = 1.10–1.31; P < 0.001). A same result appeared in the participants with or without a history of drinking, the OR for risk of HCC was higher in the subjects with a drinking history (OR = 2.03, 95% CI = 1.39–2.95; P < 0.001 vs. OR = 1.20, 95% CI = 1.10–1.31; P < 0.001). The similar situation was also seen in other subgroups of people with different gender, age, and BMI.

### Discriminatory ability of HCC for serum AFP level and genetic corrected AFP level

In order to calculate the discriminatory ability on the risk of HCC, the area under the ROC curve (AUC) was performed for the original serum AFP level and the AFP level with genetic correction. The discriminatory ability of HCC for serum AFP level after adjustment of genetic effects was higher compared with the original AFP level. With the effect of genetic correction, the AUC for the AFP level was 0.726 (95% CI: 0.652–0.799) with a sensitivity of 75.0% and a specificity of 66.3%. With compared

### Table 1. Baseline demographic and biochemical characteristics of all individuals in this study.

| Characteristic                        | Result1          |
|---------------------------------------|------------------|
| Age (year)                            | 62.09 ± 7.78     |
| Gender                                |                  |
| Male                                  | 4601 (46.9)      |
| Female                                | 5218 (53.1)      |
| BMI (kg/m²)                           | 24.33 ± 3.32     |
| Smoking status                        |                  |
| Ever                                  | 2950 (30.3)      |
| Never                                 | 6784 (69.7)      |
| Drinking status                       |                  |
| Ever                                  | 2666 (27.2)      |
| Never                                 | 7124 (72.8)      |
| Marriage status2                      |                  |
| Yes                                   | 8802 (89.9)      |
| No                                     | 992 (10.1)       |
| Education level3                      |                  |
| Yes                                   | 1016 (10.4)      |
| No                                     | 8715 (89.6)      |
| Physical activity                     |                  |
| Yes                                   | 8652 (88.5)      |
| No                                     | 1130 (11.5)      |
| Family history of cancer              |                  |
| Yes                                   | 294 (3.0)        |
| No                                     | 9525 (97.0)      |
| AFP (ng/mL)                           | 2.70 (0.98–3.90) |
| Genetic corrected AFP (ng/mL)         | 2.58 (0.86–3.72) |

Several variables are inconsistent with the total number because of the absence (<1.0%). AFP, alpha-fetoprotein; BMI, body mass index.

1The characteristics of variables are presented in the forms of number (percentage), means ± standard deviation, or medians (interquartile range).

2Married or remarried.

3College or above.

### Table 2. The SNPs associated with serum AFP level and their relative genotype effect on AFP.

| SNP        | Chr | Position (bp) | Allelic Frequency | Allele | Relative Allelic effect | XX effect | OO effect | OX effect |
|------------|-----|---------------|-------------------|--------|-------------------------|-----------|-----------|-----------|
| rs12506899 | 4   | 74,538,147    | 0.33              | T      | 1.08                    | 1.10      | 0.95      | 1.02      |
| rs2251844  | 15  | 41,623,770    | 0.47              | T      | 1.10                    | 0.92      | 1.11      | 1.00      |

For the alleles associated with serum AFP, XX: homozygous; OO: non-carriers; OX: heterozygous. AFP, alpha-fetoprotein; SNP, single-nucleotide polymorphism.

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
to the genetic corrected AFP level, the original AFP level had an AUC of 0.611 (95% CI: 0.528–0.695) with a sensitivity of 61.5% and a specificity of 56.9%. The inclusion of sequence variants associated with AFP level increased the discriminatory ability by 18.8 percentage points ($P = 0.009$).

## Discussion

This is the first study to assess the predictive value of genetic corrected AFP levels on HCC risk in a prospective cohort. Our finding shows that the effect of genetic correction could improve prediction efficiency of AFP levels for primary hepatocellular carcinoma risk in the elderly Chinese population. For the AUC to estimate the discriminatory ability on the risk of HCC, the genetic correction of AFP levels had an AUC value of 0.726 compared with the original AFP levels, an increase of 18.8%. The results of AUC analysis indicated that the prediction accuracy of genetic corrected AFP level for HCC was improved when genetic correction was taken application to the AFP level. This study suggests that the risk prediction performance of serum AFP level for HCC risk could be improved with the effect of genetic correction in the elderly Chinese population.

AFP is a kind of tumor antigen with single chain oncofetal glycoprotein approximately 70,000 Daltons in molecular weight and frequently unregulated in HCC [24]. It has been demonstrated that physiological serum levels of AFP can exhibit a dose-dependent growth-regulatory activity toward developing cells or sensitive tumor [25, 26]. On the other hand, high serum levels of AFP in HCC are associated with more aggressive tumor behavior and increased anaplasia, and are used as an indicator to monitor progression and metastasis of HCC [27, 28].

Although serum AFP level is widely used for HCC screening, its predictive value for HCC risk is currently limited. Several studies have explored the potential for AFP levels for HCC prediction and found the results were unsatisfactory [35, 36]. The inter-individual variation of serum AFP levels was found a long time ago [37]. Some studies have also found that genetic variations can affect individual levels of serum AFP [38, 39]. Studies have reported that a large proportion of the variability in AFP levels is due to heredity factors [40, 41]. And our previous finding of a genome-wide association study also demonstrated that the genetic variants have essential effect on the serum levels of AFP in Chinese. Although the underlying biological mechanism of these SNPs on serum AFP remains to be explored, the individual AFP

| Model          | OR   | 95% CI   | $P$  |
|----------------|------|----------|------|
| Model 1        | 5.05 | 2.58–9.91| <0.001|
| Model 2        | 4.85 | 2.41–7.79| <0.001|
| Model 3        | 5.34 | 2.57–11.13| <0.001|
| Model, adjusted for the other variables. | | | |

### Table 4.

| Subgroups | OR   | 95% CI   | $P$  |
|-----------|------|----------|------|
| Gender1   | Male | 2.57     | 1.42–4.65 | 0.002 |
|           | Female | 1.58     | 0.16–16.08 | 0.700 |
| Age group2 | <62 | 1.76     | 1.03–3.00 | 0.039 |
|           | ≥62 | 5.05     | 2.18–11.67 | <0.001 |
| BMI group2 | <24 | 1.28     | 0.57–2.90 | 0.550 |
|           | ≥24 | 10.19    | 4.19–24.80 | <0.001 |
| Smoking status2 | Ever | 2.15     | 1.42–3.26 | <0.001 |
|               | Never | 1.19     | 1.10–1.30 | <0.001 |
| Drinking status2 | Ever | 2.03     | 1.39–2.95 | <0.001 |
|               | Never | 1.20     | 1.10–1.31 | <0.001 |

AFP, alpha-fetoprotein; BMI, body mass index; HCC, primary hepatocellular carcinoma; OR, odds ratio; 95% CI, 95% confidence interval.

1Adjusted for age, smoking status, drinking status, education, marriage, BMI, physical activity, family history of cancer.

2Adjusted for the other variables.
levels could be estimated by these genetic variants. The SNP rs12506899 is located in the intron of \textit{AFP} gene, however, it was found to be high linked with rs6834059, which is located at the transcription factor binding site of \textit{AFP} gene and may affect the expression of \textit{AFP}. On the other hand, there was no significant association between rs12506899 and the HCC risk in the present study. It indicated that the rs12506899 has impact on serum AFP level and further improves the prediction efficiency of AFP level on HCC risk. This situation was also seen in SNP rs2251844.

However, there are still certain limitations of this study that should be considered. First, only elderly people were enrolled in this study, and therefore it may not reflect the utility of AFP in the general population. All the subjects in this study came from Dongfeng automobile enterprise, including not only locals but also the people from every area in China. Therefore, such a conclusion could be drawn with a certain representative. Second, only the SNPs associated with AFP levels for genetic correction were taken into consideration. In effect, there may be other genetic variants associated with AFP levels besides SNPs. In consideration of other genetic variants more than SNPs in the future will help to learn the true role of AFP levels with genetic correction on the prediction efficiency for cancer risk. Although there are some shortcomings, our study still has important significance that cannot be ignored for further prediction of HCC, showing the prediction efficiency of genetic correction for serum AFP level on HCC risk. These limitations may be addressed when unidentified genetic variants which are associated with AFP are identified in the future. Further analysis with a longer follow-up need to be implemented to confirm the role of serum biomarker as a predictive indicator for clinic application.

Conclusions

In conclusion, we have identified that the significance in the prediction of primary hepatocellular carcinoma could be improved by adjusting the serum AFP levels with genetic effects. The genetic correction effect on serum AFP should be considered in the clinic application of such tumor biomarkers. Further studies of genetic effects on treatment and prognosis are warranted in order to further investigate the role of this tumor biomarker in the future.

Ethical Approval

All the procedures performed in this study included human participants and experiments were according to the ethical standards of national research committee and in accordance with the 1964 Helsinki declaration. The human experimental protocols in this study were approved by the Medical Ethics Committee of the School of Public Health, Tongji Medical College, and Dongfeng General Hospital. Informed consent was obtained from all individual participants included in the study.

Acknowledgments

This research was supported by the grants from National Natural Science Foundation of China (81773520 and 81172754) for Sheng Wei.

Conflict of Interest

None declared.

References

1. Siegel, R. L., K. D. Miller, and A. Jemal. 2018. Cancer statistics, 2018. CA Cancer J. Clin. 68:7–30.
2. Chen, W., R. Zheng, P. D. Baade, S. Zhang, H. Zeng, F. Bray, et al. 2016. Cancer statistics in China, 2015. CA Cancer J. Clin. 66:115–132.
3. Tateishi, R., H. Yoshida, S. Shiina, H. Imamura, K. Hasegawa, T. Teratani, et al. 2005. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54:419–425.
4. Song, Z. Z. 2008. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:2145–2146; author reply 2146–2147.
5. Mizejewski, G. J. 2001. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp. Biol. Med. (Maywood) 226:377–408.
6. De Ioris, M., L. Brugieres, A. Zimmermann, J. Keeling, P. Brock, R. Maibach, et al. 2008. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. Eur. J. Cancer 44:545–550.
7. Rich, N., and A. G. Singal. 2014. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract. Res. Clin. Gastroenterol. 28:843–853.
8. Takada, H., K. Tsuchiya, Y. Yasui, N. Nakakuki, N. Tamaki, S. Suzuki, et al. 2016. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Cancer Med. 5:3111–3120.
9. Toyoda, H., T. Kumada, T. Tada, T. Ito, A. Maeda, Y. Kaneoka, et al. 2014. Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy. Cancer Med. 3:643–651.

10. Chen, G. G., R. L. Ho, J. Wong, K. F. Lee, and P. B. Lai. 2007. Single nucleotide polymorphism in the promoter region of human alpha-fetoprotein (AFP) gene and its significance in hepatocellular carcinoma (HCC). Eur. J. Surg. Oncol. 33:882–886.

11. Gan, Y., Q. Liang, and X. Song. 2014. Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis. Tumour Biol. 35:3953–3960.

12. Farinati, F., D. Mariano, M. De Giorgio, A. Baldan, M. Cantarini, C. Cursaro, et al. 2006. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am. J. Gastroenterol. 101:524–532.

13. Llovet, J. M., A. Burroughs, and J. Bruix. 2003. Hepatocellular carcinoma. Lancet 362:1907–1917.

14. Subwongcharoen, S., K. Leelawat, S. A. Treepongkaruna, and S. Narong. 2011. Serum AFP and AFP-L3 in clinically distinguished hepatocellular carcinoma from patients with liver masses. J. Med. Assoc. Thai. 94:S46–S51.

15. Gupta, S., S. Bent, and J. Kohlwes. 2003. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann. Intern. Med. 139:46–50.

16. Narimatsu, H., H. Iwasaki, F. Nakayama, Y. Ikehara, T. Kudo, S. Nishihara, et al. 1998. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 58:512–518.

17. Kawai, S., K. Suzuki, K. Nishio, Y. Ishida, R. Okada, Y. Goto, et al. 2008. Smoking and serum CA19-9 levels according to Lewis and secretor genotypes. Int. J. Cancer 123:2880–2884.

18. Gudmundsson, J., S. Besenbacher, P. Sulem, D. F. Gudbjartsson, I. Olafsson, S. Arinbjarnarson, et al. 2010. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci. Transl. Med. 2:62ra92.

19. He, M., C. Wu, J. Xu, H. Guo, H. Yang, X. Zhang, et al. 2014. A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and alpha fetoprotein and their associations with cancer risk. Gut 63:143–151.

20. Wang, F., J. Zhu, P. Yao, X. Li, M. He, Y. Liu, et al. 2013. Cohort Profile: the Dongfeng-Tongji cohort study of retired workers. Int. J. Epidemiol. 42:731–740.

21. Choi, B. I. 2010. Advances of imaging for hepatocellular carcinoma. Oncology 78:46–52.

22. Forner, A., J. M. Llovet, and J. Bruix. 2012. Hepatocellular carcinoma. Lancet 379:1245–1255.

23. Shen, Q., J. Fan, X.-R. Yang, Y. Tan, W. Zhao, Y. Xu, et al. 2012. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 13:817–826.

24. Ball, D., E. Rose, and E. Alpert. 1992. Alpha-fetoprotein levels in normal adults. Am. J. Med. Sci. 303:157–159.

25. Dudich, E., L. Semenkova, E. Gorbatova, I. Dudich, L. Khromykh, E. Tatulov, et al. 1998. Growth-regulative activity of human alpha-fetoprotein for different types of tumor and normal cells. Tumour Biol. 19:30–40.

26. Nakabayashi, H., T. Hashimoto, Y. Miyao, K. K. Tjong, J. Chan, and T. Tamaoki. 1991. A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma. Mol. Cell. Biol. 11:5885–5893.

27. Wang, X. W., and B. Xu. 1998. Stimulation of tumor-cell growth by alpha-fetoprotein. Int. J. Cancer 75:596–599.

28. Tajiri, H., T. Takano, H. Tanaka, K. Ushijima, A. Inui, Y. Miyoshi, et al. 2016. Hepatocellular carcinoma in children and young patients with chronic HBV infection and the usefulness of alpha-fetoprotein assessment. Cancer Med. 5:3102–3110.

29. Li, M., X. Liu, S. Zhou, P. Li, and G. Li. 2005. Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes. BMC Cancer 5:96.

30. McMahon, B. J. 2005. Epidemiology and natural history of hepatitis B. Semin. Liver Dis. 25:3–8.

31. Jin, D. K., E. C. Anderson, E. Gilbert, and M. H. Feuerman. 2005. AFP gene expression after acute diethylaminoledrazone intoxication is not Afr2 regulated. Cancer Lett. 230:211–220.

32. Marrero, J. A., Z. Feng, Y. Wang, M. H. Nguyen, A. S. Befeler, L. R. Roberts, et al. 2009. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137:110–118.

33. Schmelzer, E., L. Zhang, A. Bruce, E. Wauthier, J. Tjong, J. Chan, and T. Tamaoki. 1991. A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma. Mol. Cell. Biol. 11:5885–5893.

34. Um, S. H., C. Mulhall, A. Alisa, A. R. Ives, J. Karani, R. Williams, et al. 2004. Alpha-fetoprotein impairs APC function and induces their apoptosis. J. Immunol. 173:1772–1778.

35. Trevisani, F., P. E. D’Intino, A. M. Morselli-Labate, G. Mazzella, E. Accogli, P. Caraceni, et al. 2001. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease:
influence of HBsAg and anti-HCV status. J. Hepatol. 34:570–575.
36. Park, E. R., S. B. Kim, J. S. Lee, Y. H. Kim, D. H. Lee, E. H. Cho, et al. 2017. The mitochondrial hinge protein, UQCRH, is a novel prognostic factor for hepatocellular carcinoma. Cancer Med. 6:749–760.
37. Gillespie, J. R., and V. N. Uversky. 2000. Structure and function of alpha-fetoprotein: a biophysical overview. Biochim. Biophys. Acta 1480:41–56.
38. McMahon, B. J., S. R. Alberts, R. B. Wainwright, L. Bulkow, and A. P. Lanier. 1990. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch. Intern. Med. 150:1051–1054.
39. Zhang, B. H., B. H. Yang, and Z. Y. Tang. 2004. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 130:417–422.
40. Zhao, X., S. Parpart, A. Takai, S. Roessler, A. Budhu, Z. Yu, et al. 2015. Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM AFP hepatocellular carcinoma. Oncogene 34:5095–5104.
41. Lee, J. S., I. S. Chu, J. Heo, D. F. Calvisi, Z. Sun, T. Roskams, et al. 2004. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667–676.